Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Results of clinical trials devoted to β-adrenoblocker use in arterial hypertension (HT) are presented. Differences between β-adrenoblockers as well as β-adrenoblocker use in hy￾pertensive patients with concomitant diseases are shown. The β-adrenoblocker position in up-to-date guidelines on HT diagnosis and treatment is discussed.

About the Author

V. I. Makolkin
Moscow Medical Academy named after I. M. Setchenov
Russian Federation

Chair of Faculty Therapy N 1

Bolshaya Pirogovskaya ul. 6, Moscow, 119991 


1. Erdine S. How well is hypertension controlled in Europe? ESH Scientific Newsletter: Update on Hypertension Management. 2007;8:(3):revised version.

2. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России: информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья 2001;(2): 3-7.

3. Shalnova S.A., Deev A.D., Oganov R.G. et al. Arterial hypertension impact on mortality in Russia [abstract]. Eur Heart J 1998,19 Suppl.:705.

4. Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваскулярная терапия и профилактика 2005;(1):4-9.

5. López-Sendón J., Swedberg K., McMurray J., et al.; Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25(15):1341-62.

6. Lever A.F., Brennan P.J. MRC trial of treatment in elderly hypertensives. Clin Exp Hypertens 1993;15:941-52.

7. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995- 1003.

8. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimes of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA); a multicentre randomized controlled trial. Lancet 2005;366:895-906.

9. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-16.

10. Zanсhetti A., Bond M.G., Henning M., et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a ran￾domized, double-blind, long-term trial. Circulation 2002;106:2422-7.

11. Wilhelmsen L., Berglund G., Elmfeldt D. et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561-72.

12. Johannesson M., Dahlof B., Lindholm L.H. The cost-effectiveness of treating hypertension in elderly people - an analysis of the Swedish Trial in Old Patients with Hypertension (STOP-Hypertensuion). J Intern Med 1993;234:317-23.

13. Hansson L., Lindholm L.H., Ekborm T. et al. Randomised trial of old and new antihypertensive drugs in elderly patients; cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.

14. Wikstrand J., Warnold I., Olsson G., et al. Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA 1988;259(13):1976-82.

15. Wikstrand J. Primary prevention in patients with hypertension: comments on the clinical implications of the MAPHY Study. Metoprolol Atherosclerosis Prevention in Hypertensives Study. Am Heart J 1988; 116(1 Pt 2):338-47.

16. Wikstrand J., Warnold I., Tuomilehto J., et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 1991;17:579-88.

17. Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.

18. Bradley H.A., Wiysonge C.S., Volmink J.A., et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006;24:2131-41.

19. Wiysonge C.S., Bradley H., Mayosi B.M., et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007;(1):CD002003.

20. Кобалава Ж.Д., Толкачева В.В. Артериальная гипертония: возможности и ограничения метааналитического подхода. РМЖ 2002;10(1): 21-5.

21. NICE clinical guideline 34. Hypertension: management of hypertension in primary care. June 2006. Available at￾dia/pdf/CG034NICEguideline.pdf

22. Vikman S., Keistinen T., Tuuponen T., Kivela S.L. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration 1997;64:281-4.

23. Kuller L.H., Ockene Jk., Townsend M. et al. The epidemiology of pulmonary function and COPD mortality in the multiple risk factor intervention trial. Am Rev Respir Dis 1989;140(3 Pt 2):S76-81.

24. Sin D.D., Man S.F. Chronic odstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005;2:8-11.

25. Andrus M.R., Holloway K.R., Clark D.B. Use of beta-blockers in patients with COPD. Ann Pharmacother 2004;38:142-5.

26. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.

27. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002;137:715-25.

28. Маколкин В.И., Овчаренко С.И., Литвинова И.В. Возможность применении бета-адреноблокаторов у больных с сопутствующей патологией. Тер арх 2008;80(8):86-9.

29. Erdmann E. Safety and tolerability of beta-blockers: prejudices and reality. Eur Heart J Suppl 2009;11 Suppl A:A21-25.

30. Radack K., Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A metaanalysis of randomized controlled trials. Arch Intern Med 1991;151: 1769-76.

31. Fonarow G.C. Managing the patients with diabetes mellitus and heart failure: issues and consideration. Am J Med 2004;116 Suppl 5A:76S-88S.

32. Haas S.J., Vos T., Gilbert R.E., Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003;146:848-53.

33. Owada A., Suda S., Hata T., Miyake S. The effect of bisoprolol, a selective beta1-blocker, on glucose metabolism by long-term administration in essential hypertension. Clin Exp Hypertens 2001;23:305-16.

34. Van Bortel L., Breed J. Nebivolol in hypertension: double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993;21:856-62.

35. Чазова И.Е., Мычка В.Б. Метаболический синдром. М.: Медиа медика, 2004.

36. Fogari R., Zoppi A., Lazzari P. et al. Comparative effects on nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997;11:753-7.

37. Ахмедова О.О., Гаврилов Ю.В., Петрий В.В. и др. Антигипертензивная эффективность бета-блокаторов метопролола и небиволола при монотерапии у больных мягкой и умеренной артериальной гипертензией и ИБС в сочетании с сахарным диабетом 2 типа. Российский кардиологический журнал 2003;(2):44-8.

38. Rerkpattanapipat P., Stanek M.S., Kotler M.N.Sex and the heart: what is the role of the cardiologist? Eur Heart J 2001;22:201-8.

39. Feldman H.A., Goldstein I., Hatzichristou D.G., et al. Impotence and its medical and psyhosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.

40. Grimm R.H. Jr, Grandits G.A., Prineas .RJ. et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment Of Mild Hypertension Study (TOMHS). Hypertension 1997;29:8-14.

41. Shiri R., Koskimaki J., Hakkinen J. et al. Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res 2007;19: 208-12.

42. Wassertheil-Smoler S., Blaufox M.D., Obermann A. et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med 1991;114:613-20.

43. Silvestri A., Galetta P., Cerqueatani E. et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003;24:1928-32.

44. Frishman W.H., Burris J.F., Mroczek W.J. et al. First-line therapy with lowdose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995;35: 182-8.

45. Neutel J.M., Rolf C.N., Valentine S.N. et al. Low-dose combination therapy as first line treatment of mild to moderate hypertension: the efficacy and safety of bisoprolol/HCTZ versus amlodipine, enalapril and placebo. Cardiovasc Rev Rep 1996;17:33-45.

46. Prisant L.M., Weir M.R., Papademetriou V. et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995;130:359-66.

47. Маколкин В.И. Определено ли место β-адреноблокаторов при лечении артериальной гипертонии? Системные гипертензии. Приложение к журналу Consilium Medicum. 2006;(2):54-7.

48. Конради А.Л. Бета-блокаторы в лечении артериальной гипертензии – наступило ли время забвения? Артериальная гипертензия 2006;12(3):212-5.

49. Чазова И.Е. β-Адреноблокаторы: место их применения при артериальной гипертонии в современных условиях. Системные гипертензии. Приложение к журналу Consilium Medicum 2007;(2):4-7.

50. Бойцов С.А. Закончились ли страсти по β-адреноблокаторам? Сердце 2007;6(5):250-4.

51. Мареев В.Ю., Арболишвили Г.Н. Проблемы и перспективы β-адреноблокаторов в XXI веке: возможные позиции небиволола. Сердце 2007;6(5):240-9.

52. Панов А.В., Козулин В.Ю. Место β-адреноблокаторов в лечении артериальной гипертензии. Конфликт рекомендаций? Cердце. 2008;7(3):153-6.

53. Малай Л.Н. Бета-блокаторы в XXI веке: конец эпохи или начало бессмертия? Взгляд рядового кардиолога. Рациональная Фармакотерапия в Кардиологии. 2008;(4):85-9.

54. Марцевич С.Ю. И вновь о бета-адреноблокаторах при артериальной гипертонии. Что же рекомендовать практическому врачу? Рациональная Фармакотерапия в Кардиологии 2009;(1):83-6.

55. Терещенко С.Н. Бета-адреноблокаторы: возможности расширения показаний к применению. Consilium Mecicum 2005;7(5):392-6.

56. Mancia G., De Backer G., Dominiczak A. et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the Euro￾pean Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.

57. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика 2008; 7(приложение 2):3-32.

For citation:

Makolkin V.I. REASONS FOR Β-ADRENOBLOCKER USE IN ARTERIAL HYPERTENSION: ONE MORE TIME ABOUT PRO AND CONTRA. Rational Pharmacotherapy in Cardiology. 2009;5(2):83-88. (In Russ.)

Views: 364

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)